Chromosomal translocations encode oncogenic fusion proteins that have been proven to be
causally involved in tumorigenesis. Our understanding of whether such genomic alterations …

Cancers have the ability to develop resistance to traditional therapies, and the increasing
prevalence of these drug resistant cancers necessitates further research and treatment …

Drug resistance is a major obstacle in the field of pre-clinical and clinical therapeutics. The
development of novel technologies and targeted therapies have yielded new modalities to …

Background Cancer cell resistance to therapeutics can result from acquired or de novo-
mediated factors. Here, we have utilised advanced breast cancer cell culture models to …

Chemoresistance is a leading cause of morbidity and mortality in cancer and it continues to
be a challenge in cancer treatment. Chemoresistance is influenced by genetic and …

Anticancer drugs resistance is a complex process that arises from altering in the drug
targets. Advances in the DNA microarray, proteomics technology and the development of …

Transforming growth factor-β (TGF-β) signaling is essential in embryo development and
maintaining normal homeostasis. Extensive evidence shows that TGF-β activation acts on …

The present study was carried out to develop cisplatin-loaded chitosan nanoparticles
(CCNP) and cisplatin-loaded chitosan nanoparticle surface linked to rituximab (mAbCCNP) …

Cancer is one of the primary causes of worldwide human deaths. Most cancer patients
receive chemotherapy and radiotherapy, but these treatments are usually only partially …

Abstract “Platinum resistant” ovarian cancer was historically defined as disease recurrence
within 6 months of completion of first-line platinum-based chemotherapy, although this is …